Letters to the Editor

Tashima K , Cu-Uvin S , Caliendo A , Bose T , Gormley J , Flanigan T . Suppression of viral load in the female genital tract and cerebrospinal fluid (CSF) in patients on combination therapy including efavirenz. 9th European Congress of Clinical Microbiology and Infectious Diseases. March 21-24, 1999. Berlin, Germany.

Sustiva, full prescribing information, Bristol-Myers Squibb Company, 2002.

Wise ME , Mistry K , Reid S . Drug points: Neuropsychiatric complications of nevirapine treatment. BMJ 2002; 324(7342):879.

Morlese JF , Qazi NA , Gazzard BG , Nelson MR . Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS 2002; 16(13):1840-1841.

Treisman GJ , Kaplin AI . Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002; 16(9):1201-1215.

Fiske WD , Joshi AS , Labriola DF . An assessment of population pharmacokinetic parameters of efavirenz on nervous system symptoms and suppression of HIV-RNA. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. September 22-25, 2001. Chicago IL. (Abstract A-1727).

Gill J , Rachlis A , Walmsley S , Halman M . Canadian Expert Panel recommendations on the management of CNS symptoms related to efavirenz. Canadian Journal of Infectious Diseases 2001; 12 (Suppl C):20C-30C.

Staszewski S , Morales-Ramirez J , Tashima KT , et al. Efivarenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Eng J Med 1999; 341(25):1865-1873.

Perez-Molina JA . Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clinical Trials 2002; (4):279-286.

Lochet P , Peyriere H , Lotthe A , et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4(1):62-66.

Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002; 22(7):930-933.

Fumaz CR , Tuldra A , Ferrer MJ , et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Aquir Immune Defic Syndrome 2002; 29(3):244-253.

Zaccarelli M , Soldani F , Liuzzi G , et al. CNS side effects as main risk factor for efavirenz failure and transient HIV-RNA elevation. 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002. Seattle, WA. (Poster 720-T).

Wise ME , Mistry K , Reid S . Drug points: Neuropsychiatric complications of nevirapine treatment. BMJ 2002; 324 (7342):879.

Morlese JF , Qazi NA , Gazzard BG , Nelson MR . Nevirapine-induced neuropsychiatric complications, a class effect of nonnucleoside reverse transcriptase inhibitors? AIDS 2002; 16(13):1840-1841.

van Leth F , Hassink E , Phanuphak P , et al. Results of the 2NN Study: A randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003. Boston, MA. (Abstract 176).

Tashima KT , Caliendo AM , Ahmad M , et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999; 180(3):862-864.

Antinori A , Perno CF , Giancola ML , et al. 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002. Seattle, WA. (Poster 438-W).